Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alvotech SA ALVO

Healthcare Biotechnology
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating... see more

Recent & Breaking News (NDAQ:ALVO)

Alvotech Provides Update on Corporate Sustainability Framework

GlobeNewswire March 28, 2023

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

GlobeNewswire March 17, 2023

Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update

GlobeNewswire March 1, 2023

Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023

GlobeNewswire February 27, 2023

Settlement of Alvotech Private Share Placement Completed

GlobeNewswire February 10, 2023

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

GlobeNewswire February 9, 2023

Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)

GlobeNewswire February 6, 2023

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

GlobeNewswire January 24, 2023

Alvotech Completes $137 Million Private Share Placement

GlobeNewswire January 23, 2023

Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

GlobeNewswire January 13, 2023

Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

GlobeNewswire January 11, 2023

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

GlobeNewswire January 6, 2023

Update on U.S. Regulatory Status of AVT02, Alvotech's Proposed High-Concentration, Interchangeable Biosimilar to Humira®

GlobeNewswire December 22, 2022

Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field

GlobeNewswire December 16, 2022

Alvotech Completes $59.7 Million Private Placement

GlobeNewswire December 16, 2022

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

GlobeNewswire December 8, 2022

Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

GlobeNewswire December 7, 2022

Alvotech Announces Changes to its Leadership Team

GlobeNewswire December 1, 2022

Alvotech Secures Financing Facilities of Approximately $136 Million

GlobeNewswire November 16, 2022

Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update

GlobeNewswire November 16, 2022